A citation-based method for searching scientific literature

Karin E Kerfoot, Robert A Rosenheck, Ismene L Petrakis, Marvin S Swartz, Richard S E Keefe, Joseph P McEvoy, T Scott Stroup. Schizophr Res 2011
Times Cited: 39







List of co-cited articles
299 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.
D A Regier, M E Farmer, D S Rae, B Z Locke, S J Keith, L L Judd, F K Goodwin. JAMA 1990
33

Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences.
Howard C Margolese, Leslie Malchy, Juan Carlos Negrete, Raymond Tempier, Kathryn Gill. Schizophr Res 2004
164
20

The positive and negative syndrome scale (PANSS) for schizophrenia.
S R Kay, A Fiszbein, L A Opler. Schizophr Bull 1987
17

Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
Marvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, T Scott Stroup, Joseph P McEvoy, Jose M Canive, Del D Miller, Fred Reimherr, Mark McGee, Ahsan Khan,[...]. J Nerv Ment Dis 2006
94
17

Drug abuse in schizophrenic patients: clinical correlates and reasons for use.
L Dixon, G Haas, P J Weiden, J Sweeney, A J Frances. Am J Psychiatry 1991
420
17

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
15


Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial.
Christine Barrowclough, Gillian Haddock, Til Wykes, Ruth Beardmore, Patricia Conrod, Tom Craig, Linda Davies, Graham Dunn, Emily Eisner, Shôn Lewis,[...]. BMJ 2010
113
15


The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Marvin S Swartz, H Ryan Wagner, Jeffrey W Swanson, T Scott Stroup, Joseph P McEvoy, Fred Reimherr, Del D Miller, Mark McGee, Ahsan Khan, Jose M Canive,[...]. Schizophr Res 2008
39
12

Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis.
Johanna Koskinen, Johanna Löhönen, Hannu Koponen, Matti Isohanni, Jouko Miettunen. Schizophr Bull 2010
189
12

Medication noncompliance and substance abuse among patients with schizophrenia.
R R Owen, E P Fischer, B M Booth, B J Cuffel. Psychiatr Serv 1996
229
12

Assessing illicit drug use among adults with schizophrenia.
Richard A Van Dorn, Sarah L Desmarais, M Scott Young, Brian G Sellers, Marvin S Swartz. Psychiatry Res 2012
23
21

Diagnosis of alcohol use disorders in schizophrenia.
R E Drake, F C Osher, D L Noordsy, S C Hurlbut, G B Teague, M S Beaudett. Schizophr Bull 1990
367
12

Substance use: a powerful predictor of relapse in schizophrenia.
C D Swofford, J W Kasckow, G Scheller-Gilkey, L B Inderbitzin. Schizophr Res 1996
147
12

The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).
Giuseppe Carrà, Sonia Johnson, Paul Bebbington, Matthias C Angermeyer, Dirk Heider, Traolach Brugha, Jean-Michel Azorin, Mondher Toumi. Eur Arch Psychiatry Clin Neurosci 2012
47
12

A meta-analysis of negative symptoms in dual diagnosis schizophrenia.
Stéphane Potvin, Amir Ali Sepehry, Emmanuel Stip. Psychol Med 2006
59
12


Comorbid substance-use in schizophrenia: relation to positive and negative symptoms.
A Talamo, F Centorrino, L Tondo, A Dimitri, J Hennen, R J Baldessarini. Schizophr Res 2006
62
12

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.
D W Heinrichs, T E Hanlon, W T Carpenter. Schizophr Bull 1984
10

The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.
David A Smelson, Douglas Ziedonis, John Williams, Miklos F Losonczy, Jill Williams, Marc L Steinberg, Maureen Kaune. J Clin Psychopharmacol 2006
52
10

A neurobiological basis for substance abuse comorbidity in schizophrenia.
R A Chambers, J H Krystal, D W Self. Biol Psychiatry 2001
323
10

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.
Ismene L Petrakis, Stephanie O'Malley, Bruce Rounsaville, James Poling, Colette McHugh-Strong, John H Krystal. Psychopharmacology (Berl) 2004
76
10

Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.
Gabriel Rubio, Isabel Martínez, Guillermo Ponce, Miguel Angel Jiménez-Arriero, Francisco López-Muñoz, Cecilio Alamo. Can J Psychiatry 2006
70
10

Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.
David A Smelson, Miklos F Losonczy, Craig W Davis, Maureen Kaune, John Williams, Douglas Ziedonis. Can J Psychiatry 2002
80
10

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Matthew J Byerly, Ira D Glick, Jose M Canive, Mark F McGee, George M Simpson, Michael C Stevens, Jeffrey A Lieberman. Schizophr Bull 2003
428
10



Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients.
Roland M Jones, Paul Lichtenstein, Martin Grann, Niklas Långström, Seena Fazel. J Clin Psychiatry 2011
25
16

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.
Jonathan P Lacro, Laura B Dunn, Christian R Dolder, Susan G Leckband, Dilip V Jeste. J Clin Psychiatry 2002
862
10


Comorbidity of substance misuse and mental illness in community mental health and substance misuse services.
T Weaver, P Madden, V Charles, G Stimson, A Renton, P Tyrer, T Barnes, C Bench, H Middleton, N Wright,[...]. Br J Psychiatry 2003
157
10

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.
R C Kessler, K A McGonagle, S Zhao, C B Nelson, M Hughes, S Eshleman, H U Wittchen, K S Kendler. Arch Gen Psychiatry 1994
10


Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.
K T Mueser, P R Yarnold, D F Levinson, H Singh, A S Bellack, K Kee, R L Morrison, K G Yadalam. Schizophr Bull 1990
376
10


Reasons for increased substance use in psychosis.
Lynsey Gregg, Christine Barrowclough, Gillian Haddock. Clin Psychol Rev 2007
118
10

Prevalence of alcohol use disorders in schizophrenia--a systematic review and meta-analysis.
J Koskinen, J Löhönen, H Koponen, M Isohanni, J Miettunen. Acta Psychiatr Scand 2009
77
10

Substance misuse at presentation to an early psychosis program.
Sarah Van Mastrigt, Jean Addington, Donald Addington. Soc Psychiatry Psychiatr Epidemiol 2004
128
10

Patterns of current and lifetime substance use in schizophrenia.
I L Fowler, V J Carr, N T Carter, T J Lewin. Schizophr Bull 1998
235
10

The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.
M Lambert, P Conus, D I Lubman, D Wade, H Yuen, S Moritz, D Naber, P D McGorry, B G Schimmelmann. Acta Psychiatr Scand 2005
215
10


Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
7

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
René S Kahn, W Wolfgang Fleischhacker, Han Boter, Michael Davidson, Yvonne Vergouwe, Ireneus P M Keet, Mihai D Gheorghe, Janusz K Rybakowski, Silvana Galderisi, Jan Libiger,[...]. Lancet 2008
684
7

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Richard S E Keefe, Robert M Bilder, Sonia M Davis, Philip D Harvey, Barton W Palmer, James M Gold, Herbert Y Meltzer, Michael F Green, George Capuano, T Scott Stroup,[...]. Arch Gen Psychiatry 2007
702
7

A rating scale for extrapyramidal side effects.
G M Simpson, J W Angus. Acta Psychiatr Scand Suppl 1970
7

Schizophrenia and co-occurring substance use disorder.
Alan I Green, Robert E Drake, Mary F Brunette, Douglas L Noordsy. Am J Psychiatry 2007
101
7

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Theresa H M Moore, Stanley Zammit, Anne Lingford-Hughes, Thomas R E Barnes, Peter B Jones, Margaret Burke, Glyn Lewis. Lancet 2007
7

Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Stéphane Potvin, Emmanuel Stip, Olivier Lipp, Robert Elie, Adham Mancini-Marië, Marie-France Demers, Marc-André Roy, Roch-Hugo Bouchard, Alain Gendron. Curr Med Res Opin 2006
52
7

Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.
Steven L Sayers, E Cabrina Campbell, Janienne Kondrich, Stephan C Mann, James Cornish, Charles O'Brien, Stanley N Caroff. J Nerv Ment Dis 2005
50
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.